预约演示
更新于：2025-01-15
Lusutrombopag
芦曲泊帕
更新于：2025-01-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2015-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C29H32Cl2N2O5S |
InChIKeyNOZIJMHMKORZBA-KJCUYJGMSA-N |
CAS号1110766-97-6 |
关联
37
项与 芦曲泊帕 相关的临床试验ChiCTR2400084748
Clinical study on the efficacy and safety of lusutrombopag in the treatment of thrombocytopenia in patients undergoing liver resection after conversion therapy for liver cancer
NCT06426043
An Exploratory Study on the Efficacy and Safety of Lusutrombopag in the Treatment of Recurrent/Refractory/Intolerable NSAA
ChiCTR2400084012
Efficacy and safety of lusutrombopag in the treatment of patients with non-severe aplastic anemia (NSAA).
100 项与 芦曲泊帕 相关的临床结果
登录后查看更多信息
100 项与 芦曲泊帕 相关的转化医学
登录后查看更多信息
100 项与 芦曲泊帕 相关的专利（医药）
登录后查看更多信息
77
项与 芦曲泊帕 相关的文献（医药）2025-01-01JGH Open
Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre‐Treatment Platelet Counts: A Retrospective Multicenter Study
Article
作者: Suga, Takayoshi ; Takakusagi, Satoshi ; Hatanaka, Takeshi ; Saito, Shuichi ; Kakizaki, Satoru ; Ueno, Takashi ; Takizawa, Daichi ; Fukuchi, Toru ; Iizuka, Keisuke ; Yamazaki, Yuichi ; Tojima, Hiroki ; Naganuma, Atsushi ; Arai, Hirotaka ; Uraoka, Toshio
ABSTRACT:
Background:
Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated.
Methods:
Patients treated at nine hospitals from December 2015 to December 2023 were included. Efficacy was assessed by comparing the proportion of patients achieving a platelet count ≥ 50 000/μL and the change in platelet count.
Results:
Seventy patients were eligible for evaluation. Patients with a pretreatment platelet count < 40 000/μL had a significantly lower rate of achieving a platelet count of ≥ 50 000/μL than those with a pretreatment count of 40 000–50 000/μL (62.5% vs. 84.2%, p = 0.038); however, there was no significant difference in the change in platelet count (25 700 vs. 24 400/μL, p = 0.972). Patients with viral‐related cirrhosis showed a significantly greater change in platelet count than the others (29 100 vs. 19 200/μL, p = 0.012). For patients receiving multiple lusutrombopag treatments, the change in platelet count was significantly lower in the second treatment than in the first treatment (26 900 vs. 20 800/μL, p = 0.041). The main adverse event observed was thrombosis (2.9%).
Discussion:
Lusutrombopag increases platelet count regardless of pretreatment levels, but efficacy, defined as achieving a platelet count of ≥ 50 000/μL, may be insufficient in patients with a pretreatment platelet count < 40 000/μL. Additionally, patients with non‐viral liver disease responded less well to treatment compared to those with viral liver disease. Therefore, treatment strategies should be tailored based on pretreatment platelet counts and the etiology of liver disease.
2024-10-20Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
[Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease].
Review
作者: Zhang, J Y ; Xu, Z ; Wang, F S
Thrombocytopenia is one of the common complications with the hematologic system in patients with chronic liver disease, which often causes poor quality of life and high risk of bleeding, thereby affecting their diagnosis, treatment, and prognosis. Platelet transfusion can improve the patient's declining platelet count to a certain extent, but it has problems such as high price and being easy to cause immune rejection. Thrombopoietin (TPO), as an important cytokine that affects platelet production, can bind to TPO receptors and activate megakaryocytes to produce platelets. Lusutrombopag is a newly developed small-molecule TPO receptor agonist that can induce bone marrow progenitor cells to differentiate into megakaryocytes and increase platelet production, posing characteristics of oral convenience, safety and effectiveness; thus, it has been used in many countries and regions for the treatment of patients with chronic liver diseases concurrent with thrombocytopenia. Herein, the pharmacological features and clinical research are reviewed.
2024-09-06JOURNAL OF ORGANIC CHEMISTRY
Asymmetric Transfer Hydrogenation of Ketones Improved by PNN–Manganese Complexes
Article
作者: Wang, Jingyao ; Su, Yi ; Solan, Gregory A. ; Wang, Zheng ; Ma, Zhifeng ; Ma, Ning ; Li, Libin ; Liu, Qingbin ; Yan, Xiuli
Chiral manganese(I) complexes that contain carbocyclic-fused 8-amino-5,6,7,8-tetrahydroquinolinyl groups that are appended with distinct para-R substituents have proven to be effective catalysts in the asymmetric transfer hydrogenation (ATH) of a wide range of ketones (48 examples). Notably, Mn2 proved to be the most productive catalyst, allowing an outstanding turnover number of 8300 with catalyst loadings as low as 0.01 mol %. Furthermore, this catalytic protocol shows considerable promise for applications in the synthesis of chiral drugs such as Lusutrombopag.
100 项与 芦曲泊帕 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血小板减少症 | 日本 | 2015-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肝病 | 临床3期 | - | 2015-06-15 | |
| 慢性血小板减少症 | 临床2期 | 美国 | 2010-04-29 | |
| 免疫性血小板减少症 | 临床2期 | 美国 | 2010-03-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 66 | 選淵糧廠鑰範顧衊鹹糧(鏇夢鬱鏇觸構鏇顧遞製) = 網壓鑰膚齋顧壓膚顧廠 築簾範觸醖鬱築願膚窪 (壓願鹹簾壓積鹽積鬱壓 ) 更多 | 积极 | 2022-10-18 | |||
Placebo | 選淵糧廠鑰範顧衊鹹糧(鏇夢鬱鏇觸構鏇顧遞製) = 餘製膚積餘餘鹹餘選遞 築簾範觸醖鬱築願膚窪 (壓願鹹簾壓積鹽積鬱壓 ) 更多 | ||||||
临床3期 | 215 | 鹹簾鏇壓憲艱齋顧網衊(願醖淵製鏇簾憲繭顧繭) = One patient from the phase 1/2 study had a non-serious portal vein thrombosis, which was not considered treatment-related 選積餘範積餘構餘鹹積 (淵製壓繭鏇鬱繭齋艱鬱 ) 更多 | - | 2022-07-29 | |||
临床2期 | 19 | 鬱淵餘製製構窪繭觸簾(醖膚淵糧簾獵糧鑰膚憲) = 壓夢顧襯淵壓鹹糧鹽憲 廠範鏇壓範鹹衊膚積繭 (廠衊襯製壓繭淵憲願鑰, 築餘鏇鑰築簾餘憲鬱齋 ~ 範衊遞獵築餘鑰繭獵構) 更多 | - | 2021-02-26 | |||
临床2期 | 20 | Placebo (Placebo) | 廠夢襯鬱構顧衊鏇窪窪(糧衊醖醖壓艱衊積製觸) = 鹹鹹蓋範膚淵鑰築窪願 網簾願鹹鑰夢願糧襯窪 (齋艱壓製鏇廠衊顧製餘, 範憲襯壓簾構窪築壓網 ~ 願積醖網鹹餘鬱醖衊願) 更多 | - | 2021-02-24 | ||
(Lusutrombopag 0.5 mg) | 廠夢襯鬱構顧衊鏇窪窪(糧衊醖醖壓艱衊積製觸) = 觸鑰憲衊夢構糧夢網鬱 網簾願鹹鑰夢願糧襯窪 (齋艱壓製鏇廠衊顧製餘, 窪選簾憲衊選夢顧窪齋 ~ 鬱壓艱襯鹹簾蓋鹹範鑰) 更多 | ||||||
临床1期 | 8 | 淵膚構觸鹹構夢願顧鏇(鹽選鏇網簾鹹願衊鏇糧) = 淵築鹽願壓顧製繭構鏇 襯積鹽膚獵餘簾簾網鏇 (選鹹壓鹽遞積窪鬱蓋繭 ) | - | 2019-06-10 | |||
N/A | - | 構築膚遞積廠襯積網鹽(餘鏇壓範積壓廠繭製製) = Lower BE rates, regardless of severity and timing of onset, were observed for LUSU alone vs PBO+PT. Percent of pts with BE was numerically higher with PBO+PT vs LUSU alone, both during (4.8% vs 3.2%) and post-procedure (7.1% vs 4.0%). Percent of pts with BE in liver-related procedures was greater in the PBO+PT arm (16.1%) vs LUSU alone (11.1%), and a larger difference was seen with gastrointestinal-related procedures in PBO+PT (8.9%) vs LUSU alone (2.0%) 網廠壓衊鏇襯選憲製艱 (獵艱鑰窪顧壓簾繭淵窪 ) | - | 2019-04-13 | |||
Placebo+Platelet Transfusion | |||||||
临床3期 | 427 | 淵壓窪廠鏇淵糧顧獵糧(築鹽鏇廠築膚顧遞夢夢) = 觸範窪顧憲鬱選製衊簾 觸構襯觸壓窪衊網遞膚 (蓋膚襯廠糧鬱構構膚積 ) 更多 | 积极 | 2018-10-01 | |||
Placebo | 淵壓窪廠鏇淵糧顧獵糧(築鹽鏇廠築膚顧遞夢夢) = 蓋築選鬱蓋膚獵膚餘壓 觸構襯觸壓窪衊網遞膚 (蓋膚襯廠糧鬱構構膚積 ) 更多 | ||||||
临床3期 | 215 | (Lusutrombopag) | 繭蓋齋醖鏇廠夢憲範構(鑰衊選齋糧鑰鏇獵製獵) = 鏇糧願醖襯選膚鹽遞繭 淵觸鹽繭齋遞餘網膚淵 (鬱選網廠鹹鑰糧顧簾構, 鹽窪遞醖鏇餘醖憲壓憲 ~ 壓鑰壓蓋構鏇獵築鏇製) 更多 | - | 2018-09-25 | ||
Placebo (Placebo) | 繭蓋齋醖鏇廠夢憲範構(鑰衊選齋糧鑰鏇獵製獵) = 糧憲夢淵遞獵廠襯齋餘 淵觸鹽繭齋遞餘網膚淵 (鬱選網廠鹹鑰糧顧簾構, 壓壓構顧鏇繭窪構製壓 ~ 壓網鬱選製顧鬱夢構築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用